Patents by Inventor Maureen D. O'Connor
Maureen D. O'Connor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12084510Abstract: Herein described are antibodies to epidermal growth factor receptor (EGER) having an EGER binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.Type: GrantFiled: February 21, 2020Date of Patent: September 10, 2024Assignees: Gilead Sciences, Inc., National Research Council of CanadaInventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville, Suzanne Grothe
-
Publication number: 20240254195Abstract: There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGF? superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and/or low red blood cell levels (such as anemia).Type: ApplicationFiled: December 22, 2023Publication date: August 1, 2024Inventors: Maureen D. O'CONNOR-MCCOURT, Vannakambadi K. GANESH, Gilles TREMBLAY, Gauthier SCHANG
-
Publication number: 20240101641Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-?) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.Type: ApplicationFiled: August 29, 2023Publication date: March 28, 2024Applicant: National Research Council of CanadaInventors: Anne E.G. LENFERINK, John C. Zwaagstra, Traian Sulea, Maureen D. O'Connor-McCourt
-
Patent number: 11866481Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-?) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.Type: GrantFiled: March 1, 2018Date of Patent: January 9, 2024Assignee: National Research Council of CanadaInventors: Anne E. G. Lenferink, John C. Zwaagstra, Traian Sulea, Maureen D. O'Connor-McCourt
-
Publication number: 20220204587Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-?) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.Type: ApplicationFiled: March 1, 2018Publication date: June 30, 2022Inventors: Anne E.G. LENFERINK, John C. ZWAAGSTRA, Traian SULEA, Maureen D. O'CONNOR-MCCOURT
-
Publication number: 20220169702Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-beta) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.Type: ApplicationFiled: November 10, 2021Publication date: June 2, 2022Applicant: National Research Council of CanadaInventors: John C. Zwaagstra, Traian Sulea, Maria L. Jaramillo, Maureen D. O'Connor, Anne E.G. Lenferink
-
Publication number: 20210238302Abstract: The present invention provides a set of Carbonic Anhydrase-IX monoclonal antibodies (CA-IX mAbs) that bind with high affinity to cell-surface expressed hCA-IX and has enzyme inhibiting characteristics. These mAbs have the potential to become the next biologics for the treatment of renal and possibly other types of cancer.Type: ApplicationFiled: April 26, 2019Publication date: August 5, 2021Inventors: Anne E. G. LENFERINK, Maureen D. O'CONNOR
-
Publication number: 20200325243Abstract: Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.Type: ApplicationFiled: February 21, 2020Publication date: October 15, 2020Inventors: Ilia Alexandre TIKHOMIROV, Maria L. JARAMILLO, Maureen D. O'CONNOR-MCCOURT, Traian SULEA, Renald GILBERT, Bruno GAILLET, Jason BAARDSNES, Myriam BANVILLE, Suzanne GROTHE
-
Publication number: 20200231652Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-beta) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.Type: ApplicationFiled: August 31, 2016Publication date: July 23, 2020Applicant: National Research Council of CanadaInventors: John C. Zwaagstra, Traian Sulea, Maria Jaramillo, Maureen D. O'Connor, Anne E.G. Lenferink
-
Patent number: 10570211Abstract: Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.Type: GrantFiled: January 20, 2012Date of Patent: February 25, 2020Assignees: GILEAD SCIENCES, INC., NATIONAL RESEARCH COUNCIL OF CANADAInventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville, Suzanne Grothe
-
Patent number: 10487153Abstract: The present invention relates to isolated or purified antibodies or fragments thereof specific for Carbohydrate Anhydrase IX (CA-IX) and their use as therapeutic tools. Specifically, the present invention is directed to high-affinity Carbohydrate Anhydrase IX-specific antibodies and fragments thereof and their use as antibody-drug conjugates. Compositions for use in therapy as well as therapeutic methods are also described.Type: GrantFiled: June 10, 2016Date of Patent: November 26, 2019Assignee: National Research Council of CanadaInventors: Anne E. G. Lenferink, Maureen D. O'Connor, Anne Marcil, Yves Durocher
-
Publication number: 20190194349Abstract: An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGY57TR59YADSVKG (SEQ ID No. 2) CDR3 WGGDGFYAMDY (SEQ ID No. 3). For the light chain: CDR1 RASQDVN30TAVA (SEQ ID No. 4) CDR2 SASF53LYS (SEQ ID No. 5) CDR3 QQHY92TTPPT (SEQ ID NO. 6). At least one of Y57, R59, N30, F53, and Y92 is substituted by an amino acid that confers on said antibody a reduced erbB2 binding affinity (Kd) that is in the range from 0.1 nM to 100 nM. The substitution is other than N30A, F53N, Y92A and Y92F when there is a single substitution in the antibody light chain.Type: ApplicationFiled: December 31, 2018Publication date: June 27, 2019Inventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville
-
Patent number: 10208129Abstract: An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGY57TR59 YADSVKG (SEQ ID No. 2) CDR3 WGGDGFYAMDY (SEQ ID No. 3) For the light chain: CDR1 RASQDVN30TAVA (SEQ ID No. 4) CDR2 SASF53LYS (SEQ ID No. 5) CDR3 QQHY92TTPPT (SEQ ID No. 6). At least one of Y57, R59, N30, F53, and Y92 is substituted by an amino acid that confers on said antibody a reduced erbB2 binding affinity (Kd) that is in the range from 0.1 nM to 100 nM. The substitution is other than N30A, F53N, Y92A and Y92F when there is a single substitution in the antibody light chain.Type: GrantFiled: December 2, 2011Date of Patent: February 19, 2019Assignee: National Research Council of CanadaInventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes
-
Publication number: 20180186893Abstract: The present invention relates to isolated or purified antibodies or fragments thereof specific for Carbohydrate Anhydrase IX (CA-IX) and their use as therapeutic tools. Specifically, the present invention is directed to high-affinity Carbohydrate Anhydrase IX-specific antibodies and fragments thereof and their use as antibody-drug conjugates. Compositions for use in therapy as well as therapeutic methods are also described.Type: ApplicationFiled: June 10, 2016Publication date: July 5, 2018Applicant: National Research Council of CanadaInventors: Anne E.G. Lenferink, Maureen D. O'Connor, Anne Marcil, Yves Durocher
-
Patent number: 8987417Abstract: The present invention addresses limitations of prior art receptor-based traps through a methodology called the clamp/click/cleave (CCC) approach. Two fusion proteins each comprising a binding domain fused to a coiled-coil are non-covalently dimerized through the coiled-coil (clamp), and the dimer so formed is stabilized by a covalent disulphide bond (click) between cysteine residues located on the fusion proteins between the binding domains and coiled-coils. Once the disulphide bond has formed, the coiled-coils are subsequently removed (cleave) by cleaving the fusions proteins at cleavage sites located between the cysteine residues and the coiled-coils to provide the covalently dimerized bivalent binding agent of the present invention. Such binding agents are useful in the treatment and diagnosis of disease states characterized by production and/or overexpression of a ligand to which the binding domains bind.Type: GrantFiled: November 28, 2011Date of Patent: March 24, 2015Assignee: National Research Council of CanadaInventors: John C. Zwaagstra, Maureen D. O'Connor-McCourt, Traian Sulea, Catherine Collins, Myriam Banville, Maria L. Jaramillo
-
Patent number: 8734760Abstract: The invention provides multivalent ligand binding agents (traps) for members of the TGF-? superfamily and polypeptide linkers and methods for making and using such constructs. The traps may be used as therapeutic or diagnostic (imaging or non-imaging) agents for diseases/disorders caused by over-production/activity of the target ligand. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-? superfamily, the agent having the general structure I: (<bd1>-linker1)k-[{<bd1>-linker2-<bd2>-linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h, where: n and h are independently greater than or equal to 1; d, f, m and k are independently equal to or greater than zero; bd's are polypeptide binding domains having an affinity for the same member of the TGF-? superfamily; and, linkers are unstructured polypeptide sequences.Type: GrantFiled: October 18, 2012Date of Patent: May 27, 2014Assignee: National Research Coucil of CanadaInventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baardsnes
-
Patent number: 8658135Abstract: The invention provides hetero-multivalent ligand binging agents (traps) for members of the TGF-? superfamily, as well as methods for making and using such constructs. In an embodiment of the invention there is provided a hetero-multivalent binding agent with affinity for a member of the TGF-? superfamily. The agent comprises the general structure I: (<bd1>-linker1)k-[{<bd1>-linker2-<bd2>-linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h, where bd1, bd2, bd3 and bd4 are polypeptide binding domains having an affinity for different sites on the same member or for different members of the TGF-? superfamily; at least two of bd1, bd2, bd3, and bd4 are different from each other.Type: GrantFiled: September 17, 2009Date of Patent: February 25, 2014Assignee: National Research Council of CanadaInventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baardsnes, Catherine Collins
-
Patent number: 8629240Abstract: Peptides are disclosed that are useful for molecular imaging or diagnosis of a disease state, such as cancer, in which clusterin is upregulated.Type: GrantFiled: April 15, 2010Date of Patent: January 14, 2014Assignee: National Research Council of CanadaInventors: Rana Filfil, Dmitri Tolkatchev, Feng Ni, Maureen D. O'Connor-McCourt, Anne E. G. Lenferink
-
Publication number: 20130295086Abstract: Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.Type: ApplicationFiled: January 20, 2012Publication date: November 7, 2013Applicants: NATIONAL RESEARCH COUNCIL OF CANADA, YM BIOSCIENCES INC.Inventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville, Suzanne Grothe
-
Patent number: 8574548Abstract: The invention provides multivalent ligand binding agents (traps) for members of the TGF-? superfamily and polypeptide linkers and methods for making and using such constructs. The traps may be used as therapeutic or diagnostic (imaging or non-imaging) agents for diseases/disorders caused by over-production/activity of the target ligand. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-? superfamily, the agent having the general structure I: (<bd1>-linker1)k-[{<bd1>-linker2-<bd2>-linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h, where: n and h are independently greater than or equal to 1; d, f, m and k are independently equal to or greater than zero; bd's are polypeptide binding domains having an affinity for the same member of the TGF-? superfamily; and, linkers are unstructured polypeptide sequences.Type: GrantFiled: October 18, 2012Date of Patent: November 5, 2013Assignee: National Research Council of CanadaInventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baardsnes